Quick answer: Lenire is a prescription device that pairs sounds played through headphones with mild electrical stimulation of the tongue, an approach called bimodal neuromodulation. The US Food and Drug Administration authorized it in March 2023 to temporarily relieve the symptoms of at least moderate tinnitus in adults. In company-funded clinical trials, many users reported meaningful improvement on standard tinnitus questionnaires after 6 to 12 weeks of daily use. It is not a cure, not everyone benefits, and none of the trials compared it against a true placebo.
Tinnitus, the ringing, hissing or buzzing that people hear when no outside sound is present, is very common and often hard to treat. In October 2026 it got fresh attention when the main US ear, nose and throat society added bimodal neuromodulation to its updated tinnitus guideline. Here is how Lenire works, what the trials found, and what remains uncertain.
What is tinnitus, and why is it so hard to treat?
According to the US National Institute on Deafness and Other Communication Disorders (NIDCD), tinnitus affects an estimated 10 to 25% of adults. It is usually linked to hearing loss, and researchers think the brain plays a central role: when the ear sends less signal, circuits in the auditory system can become overactive and generate a phantom sound.
The NIDCD notes that there is no cure. The established approaches aim to make tinnitus less intrusive rather than switch it off. They include hearing aids, sound therapy, cognitive behavioral therapy (CBT) and tinnitus retraining therapy. There are no FDA-approved drugs for tinnitus.
How does Lenire work?
Lenire was developed by Neuromod Devices, a company based in Dublin, Ireland. The system has three parts: a pair of Bluetooth headphones, a small mouthpiece called the Tonguetip that rests on the tongue and delivers mild electrical pulses, and a handheld controller. Patients use it at home, typically for about an hour a day, after a prescription and fitting by a clinician with tinnitus experience.
Why the tongue?
The idea behind “bimodal” treatment is to stimulate two senses at once. The tongue is densely supplied with nerves that send signals into the brainstem. By delivering those touch signals at the same time as carefully designed sounds, the developers aim to encourage the brain’s auditory circuits to change how they behave. The exact mechanism in humans is still being studied, and the evidence so far comes from measuring symptoms, not from directly observing the circuits.
What did the FDA actually approve?
On March 6, 2023, the FDA granted Lenire a De Novo authorization (DEN210033), the route used for new types of low-to-moderate-risk devices with no existing equivalent. It created a new Class II category for “combined acoustic and electrical external stimulation” devices for tinnitus.
The approved wording is specific: the device is intended to temporarily relieve the symptoms of tinnitus in patients 18 and older with at least moderate tinnitus, as measured by the Tinnitus Handicap Inventory (THI). The FDA’s decision summary lists possible risks including skin or tissue reaction, irritation, pain, headache, a temporary increase in tinnitus during treatment, and hearing damage if sound is too loud.
What did the clinical trials find?
Three large trials, all run with Neuromod funding or involvement, form most of the evidence. Results are reported on two questionnaires: the THI and the Tinnitus Functional Index (TFI). On the THI, a drop of about 7 points is commonly treated as a clinically meaningful change.
TENT-A1 (2020): 326 patients
The first trial, published in Science Translational Medicine, randomly assigned 326 adults with chronic tinnitus in Dublin and Regensburg, Germany, to three versions of the treatment for 12 weeks. Average THI scores fell by about 13.5 to 14.6 points across the groups, and improvements were still present at 12 months for some settings. Compliance was high (about 84%), and no serious treatment-related adverse events were reported. However, all three groups received active treatment, so the trial could not show how much of the benefit came from placebo effects or natural fluctuation.
TENT-A2 (2022): changing settings mid-course
The second trial, published in Scientific Reports, fitted 191 participants and changed stimulation settings at week 6 to reduce habituation. Average THI scores fell by 18.5 points at the end of treatment and by 20.2 points at 12 months, and about 70% of participants reported benefit. An exploratory arm suggested that the tongue stimulation, not sound alone, was important for the effect. Again, there was no sham group.
TENT-A3 (2024): a mixed result
The third trial, published in Nature Communications, enrolled 112 people who each received 6 weeks of sound-only therapy followed by 6 weeks of combined sound and tongue stimulation. In the full group, it did not meet its primary goal: the share of responders was not higher with the bimodal phase than with sound alone. In the pre-specified subgroup with moderate or worse tinnitus, 58.6% responded to bimodal treatment versus 43.2% to sound alone, a statistically significant difference. The authors note that a true sham was not possible, because people can feel the tongue stimulation.
What the evidence does and doesn’t show
- It does show that many people with moderate or worse tinnitus report less distress after using the device daily for several weeks, that most can stick with it, and that serious side effects were not reported in the trials.
- It does not show that Lenire silences tinnitus, works for everyone, or beats a placebo, since no trial used a sham control.
- Durability is unclear. Follow-up has extended to about 12 months. “How durable are the effects? We don’t really know yet,” audiologist Marc Fagelson told NPR in 2024.
- Some people get worse at first. The charity Tinnitus UK notes that about a third of trial participants had a temporary worsening of their tinnitus. (Tinnitus UK discloses that Neuromod is one of its corporate supporters.)
- Cost is a barrier. NPR reported one patient paying about $4,000 out of pocket because insurance did not cover it.
This pattern is common in medical research: promising, consistent signals from industry-funded studies that still need independent, placebo-controlled confirmation. We saw a similar need for careful reading in our coverage of a randomized trial on ginger and cholesterol and of what the research says about honey for coughs.
What changed in the 2026 tinnitus guideline?
On October 12, 2026, the American Academy of Otolaryngology–Head and Neck Surgery Foundation (AAO-HNSF) published an updated clinical practice guideline on tinnitus. It contains 16 key action statements, including new statements on bimodal neuromodulation, and it advises against routinely using medications, dietary supplements or repetitive transcranial magnetic stimulation (rTMS) to treat tinnitus.
Neuromod has described the inclusion as making Lenire a standard of care. The academy’s own announcement does not use that phrase. According to Medical Daily’s reading of the guideline, clinicians “may” recommend bimodal neuromodulation, which places it among the options to discuss with patients rather than a first-line requirement. The full text is available in Otolaryngology–Head and Neck Surgery.
Who might consider it?
Based on the FDA indication and the trial data, Lenire is aimed at adults whose tinnitus is at least moderately bothersome. Anyone with new, one-sided or pulsing tinnitus, sudden hearing changes, or dizziness should see a doctor first, because those can signal conditions that need their own treatment. A hearing test and a conversation about established options such as hearing aids, sound therapy and CBT remain the usual starting point. Tinnitus is ultimately a brain-and-nervous-system problem, a theme that also appears in research on the gut-brain connection in Parkinson’s disease. For more evidence-focused health and science stories, see our science section.
This article is for general information and is not medical advice. Talk to a qualified clinician about your own symptoms.
Frequently asked questions
Does Lenire cure tinnitus?
No. The FDA authorized it to temporarily relieve tinnitus symptoms. In trials, many users reported less distress, but the sound usually did not disappear, and long-term durability beyond about a year has not been established.
How long does Lenire take to work?
The trials measured results after 6 to 12 weeks of daily use, usually about 60 minutes a day. Some participants felt temporarily worse before improving.
Is Lenire safe?
No serious device-related adverse events were reported in the main trials. The FDA lists possible risks such as tongue or skin irritation, pain, headache, a temporary increase in tinnitus, and hearing damage if sound levels are too high.
Was Lenire tested against a placebo?
No. The trials compared different stimulation settings or compared sound alone with sound plus tongue stimulation. Because users can feel the tongue stimulation, a true sham version is difficult to design.
Is Lenire covered by insurance?
Coverage varies. NPR reported in 2024 that one US patient paid about $4,000 out of pocket. Check with your insurer and clinic before starting.
Sources: FDA De Novo DEN210033; Conlon et al., Science Translational Medicine (2020); Conlon et al., Scientific Reports (2022); Boedts et al., Nature Communications (2024); NIDCD; AAO-HNSF; Tinnitus UK; NPR.
Featured image: a pair of over-ear headphones, illustrating the sound component of tinnitus therapy (not the Lenire device). Photo by PJ, CC BY-SA 3.0, via Wikimedia Commons.
